Three Pharma Companies Seek to Address FDA Rejections

Iterum Therapeutics will head back into the clinic to meet regulatory requirements to refile a New Drug Application (NDA) for oral sulopenem, which has been developed to treat uncomplicated urinary tract infections (uUTI).